Key result
Treatment with β-blockers and/or angiotensin antagonists in patients receiving anthracyclines resulted in higher post-chemotherapy LVEF compared to control (MD 6.06%; 95% CI 0.54-11.58; p=0.03).
Why the study?
Do β-blockers and/or angiotensin antagonists prevent early-onset anthracyclines-induced left ventricular dysfunction in adult patients?
Population
Adult patients (age >18 years) treated with anthracyclines-based regimens
Comparison
β-blockers and/or angiotensin antagonists vs Control (either no treatment or placebo)
Design
Meta-analysis
Authors
Loading...
Supports prophylactic β-blockers or angiotensin antagonists during anthracycline therapy; extends Level 1 evidence for LVEF preservation in cardio-oncology.
Meta-Analysis
Do β-blockers and/or angiotensin antagonists prevent early-onset anthracyclines-induced left ventricular dysfunction in adult patients?
Mean Difference: 6.06 (95% CI 0.54–11.58)
Absolute Event Rate: 64.03% vs 57.48%
p-value: p=0.03
Prophylactic use of beta-blockers and angiotensin antagonists preserves LVEF in adult patients receiving anthracycline chemotherapy, particularly at higher cumulative doses.
Yun et al. (2015) conducted a meta-analysis in Anthracyclines-induced cardiotoxicity. β-blockers and/or angiotensin antagonists vs. Control (no treatment or placebo) was evaluated on Post-chemotherapy left ventricular ejection fraction (LVEF) (MD 6.06, 95% CI 0.54-11.58, p=0.03). Treatment with β-blockers and/or angiotensin antagonists in patients receiving anthracyclines resulted in higher post-chemotherapy LVEF compared to control (MD 6.06%; 95% CI 0.54-11.58; p=0.03).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: